SOLANA BEACH, Calif. , Sept. 01, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer R .Ph., President and Chief Executive Officer, and Matt D’Onofrio, Chief
Approximately 162% growth in product sales, 152% growth in prescriptions and 57% increase in new prescribers for Gimoti ® Extends cash runway into third quarter of 2022 SOLANA BEACH, Calif. , Aug. 12, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company
SOLANA BEACH, Calif. , Aug. 05, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that the Company is scheduled to release its second quarter 2021 financial results
Participating and Sponsorship in Upcoming Digestive Health Virtual Walk SOLANA BEACH, Calif. , Aug. 02, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma ® (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA ™ , a leading provider of global
Program intends to expand awareness and trial of GIMOTI among non-prescribing healthcare providers SOLANA BEACH, Calif. , July 14, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced
Extends commitment toward supporting patients experiencing Diabetic Gastroparesis through focused collaborations and Sponsorship of the 30th Anniversary Digestive Health Virtual Walk SOLANA BEACH, Calif. , CHICAGO , and MOUNT PLEASANT, S.C. , June 29, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
Results demonstrate continued increased awareness and intent to prescribe GIMOTI SOLANA BEACH, Calif. and CHICAGO , June 15, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, a
SOLANA BEACH, Calif. , June 08, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its US patent No. 11,020,361 for Gimoti ® (metoclopramide) nasal spray is now listed in the
New patent expands intellectual property protection for nasal delivery of metoclopramide and is expected to be FDA Orange Book listed SOLANA BEACH, Calif. , June 02, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for
Evoke is committed to meeting patients online, where they search for answers New campaign leverages Facebook to satisfy significant unmet need for education and community SOLANA BEACH, Calif. and CHICAGO , May 27, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
